[1]
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018 May 15:71(19):e127-e248. doi: 10.1016/j.jacc.2017.11.006. Epub 2017 Nov 13
[PubMed PMID: 29146535]
Level 3 (low-level) evidence
[2]
Krasińska B, Cofta S, Szczepaniak-Chicheł L, Rzymski P, Trafas T, Paluszkiewicz L, Tykarski A, Krasiński Z. The Effects of Eplerenone on the Circadian Blood Pressure Pattern and Left Ventricular Hypertrophy in Patients with Obstructive Sleep Apnea and Resistant Hypertension-A Randomized, Controlled Trial. Journal of clinical medicine. 2019 Oct 13:8(10):. doi: 10.3390/jcm8101671. Epub 2019 Oct 13
[PubMed PMID: 31614891]
Level 1 (high-level) evidence
[3]
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England journal of medicine. 2003 Apr 3:348(14):1309-21
[PubMed PMID: 12668699]
[4]
Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. The New England journal of medicine. 2011 Jan 6:364(1):11-21. doi: 10.1056/NEJMoa1009492. Epub 2010 Nov 14
[PubMed PMID: 21073363]
[5]
Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2016 May:101(5):1889-916. doi: 10.1210/jc.2015-4061. Epub 2016 Mar 2
[PubMed PMID: 26934393]
Level 3 (low-level) evidence
[6]
Prejean SP, Din M, Reyes E, Hage FG. Guidelines in review: Comparison of the 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes and the 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. 2018 Jun:25(3):769-776. doi: 10.1007/s12350-017-1137-z. Epub 2017 Dec 11
[PubMed PMID: 29230658]
[7]
O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013 Jan 29:61(4):e78-e140. doi: 10.1016/j.jacc.2012.11.019. Epub 2012 Dec 17
[PubMed PMID: 23256914]
Level 3 (low-level) evidence
[8]
Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clinical cardiology. 2008 Apr:31(4):153-8. doi: 10.1002/clc.20324. Epub
[PubMed PMID: 18404673]
[9]
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15:128(16):1810-52. doi: 10.1161/CIR.0b013e31829e8807. Epub 2013 Jun 5
[PubMed PMID: 23741057]
Level 3 (low-level) evidence
[10]
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979). 2018 Jun:71(6):1269-1324. doi: 10.1161/HYP.0000000000000066. Epub 2017 Nov 13
[PubMed PMID: 29133354]
Level 3 (low-level) evidence
[11]
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England journal of medicine. 1999 Sep 2:341(10):709-17
[PubMed PMID: 10471456]
Level 1 (high-level) evidence
[12]
Dimitriadis G, Papadopoulos V, Mimidis K. Eplerenone reverses spironolactone-induced painful gynaecomastia in cirrhotics. Hepatology international. 2011 Jun:5(2):738-9. doi: 10.1007/s12072-010-9235-x. Epub 2010 Dec 21
[PubMed PMID: 21484105]
[13]
Karagiannis A,Tziomalos K,Kakafika A,Florentin M,Athyros VG, Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2007 Jan;
[PubMed PMID: 17018542]
[14]
Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. The New England journal of medicine. 2004 Aug 5:351(6):543-51
[PubMed PMID: 15295047]
Level 1 (high-level) evidence